Skip to content
2000
Volume 14, Issue 1
  • ISSN: 1871-5257
  • E-ISSN: 1875-6182

Abstract

Background: More than 50% of oncohematological patients suffer from pain syndrome, mostly originating from the bone, which often include nociceptive and neuropathic complaints. Tapentadol, a recently available treatment option for cancer pain, exerts a dual analgesic mechanisms (opioid and noradrenergic), allowing for a high clinical efficacy as well as for a reduction in adverse events compared to traditional opioids. Aim: To explore the safety and efficacy of tapentadol as a suitable agent for the pain management in the setting of oncohematology. Methods: Our observational study included 36 patients with basal pain intensity (NRS) ranging from 5 to 10. Tapentadol prolonged release (PR) was given at the initial dose of 50 mg BID and careful titrated according to the achieved pain control. Results. Tapentadol PR was given at the dosages ranging from 200 and 260 mg/day after a careful titration, allowed for a clinically (-7 points NRS) remarkable reduction of pain intensity without any significant side effects. Conclusion: In oncohematological patients on pain, tapentadol PR was effective and well tolerated, so representing a suitable treatment option in this difficult setting.

Loading

Article metrics loading...

/content/journals/chamc/10.2174/1871525714666160405110833
2016-04-01
2024-12-23
Loading full text...

Full text loading...

/content/journals/chamc/10.2174/1871525714666160405110833
Loading

  • Article Type:
    Research Article
Keyword(s): hematological malignancies; Hematology; pain; stromal cells; syndromes; tapentadol
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test